aluxum Morgan Stanley has started Myriad Genetics ( NASDAQ: MYGN ) off at equal-weight, as it says it is awaiting evidence that the testing company can sustain growth acceleration. The firm has a $32 price target (~12% upside based on Sept. 18 close).
Analyst.
